Carbohydrate antigen 19-9 (CA 19-9) can rise in subsets of colorectal cancer (CRC), most prominently in mucinous phenotypes and tumors that elaborate secreted mucin glycoproteins, even when inflammatory cytokines such as interleukin 6 (IL-6) are normal or declining. Here, we expand the mechanistic rationale for this biomarker discordance and convert it into a concise, testable clinical workflow. First, CA 19-9 expression reflects the sialyl Lewis^a (sLe^a) epitope carried on mucins such as MUC1/MUC5AC; once the underlying glycosylation machinery is engaged (e.g., FUT3 and ST3Gal-III), biosynthesis can continue despite suppression of NF-κB/STAT3-linked inflammatory signaling, yielding persistent antigen shedding even as IL-6 falls. Second, hypoxia and angiogenic drive provide an inflammation-independent route to heightened mucin production: stabilization of HIF-1α and induction of VEGF promote glycoprotein synthesis and increase cellular turnover in hypoxic niches, augmenting CA 19-9 release without elevating systemic cytokines. Third, subclonal evolution can generate phenotypic decoupling; emergent KRAS/BRAF/TP53-altered clones may display a mucin-high, inflammation-low program, producing rising CA 19-9 while IL-6 remains quiescent. Fourth, extratumoral sources, especially cholestasis, biliary obstruction, or cholangitis, raise CA 19-9 independent of cancer activity and must be considered whenever imaging is stable. Fifth, effective therapy can transiently elevate CA 19-9 via tumor lysis or exosome-mediated shedding even as overall inflammatory tone declines, creating short-lived spikes that should be interpreted in a temporal context. Operationally, we propose an imaging anchored algorithm that integrates molecular and biochemical stratification. The trigger is a verified CA 19-9 rise with low/normal IL-6. Step 1: perform contrast CT/MRI to assess for new or enlarging lesions and add ultrasound/MRCP when symptoms or cholestatic laboratory values suggest a biliary contribution. Step 2a (progression present): obtain circulating tumor DNA (ctDNA) to detect emergent KRAS/BRAF/TP53 subclones and, when clinically appropriate, escalate toward targeted or combination therapy while continuing to track CA 19-9, CEA, and ctDNA response. Step 2b (no radiographic progression): evaluate the hepatobiliary tree with bilirubin, alkaline phosphatase, γ-glutamyltransferase, and ultrasound/MRCP; treat obstruction or inflammation and repeat markers after resolution. If biliary evaluation is negative, Step 3: deploy a stratification panel, MUC1/MUC5AC expression, FUT3/ST3Gal-III activity, and hypoxia/angiogenesis markers (HIF-1α, VEGF), to document an inflammation-independent mucin/glycan drive; integrate conventional markers (CEA, LDH-A, β2-microglobulin) to contextualize tumor burden. Finally, reassess trends after any therapeutic change to distinguish true progression from treatment transient release. This framework clarifies three common scenarios: (A) subclone driven progression (new lesions plus positive ctDNA) warranting escalation despite low IL-6; (B) biliary confounding (stable imaging with cholestatic tests) prompting biliary management and deferred oncologic change; and (C) therapy related transients (post treatment CA 19-9 spikes with improving imaging and falling IL-6) best managed by continued monitoring. Overall, rising CA 19-9 with low IL-6 is biologically coherent and clinically interpretable when framed by mucin biology, hypoxia, clonal dynamics, and hepatobiliary physiology. The proposed stepwise algorithm, imaging first; ctDNA when progression; biliary tests when stable; optional mucin/glycosylation/hypoxia profiling; iterative reassessment, aims to prevent misinterpretation of isolated CA 19-9 rises and to guide timely, mechanism-appropriate decisions, including escalation toward targeted therapy when clonal evolution is identified.